10月7日,ClinicalTrials.gov网站显示,辉瑞已终止两项Sisunatovir治疗呼吸道合胞病毒(RSV)感染的临床研究。据外媒Fierce Biotech报道,辉瑞的一位发言人表示:“Sisunatovir的临床开发面临持续的挑战,包括与抗酸药的药物相互作用。虽然辉瑞一直在努力解决这些挑战,但最终决定终止Sisunatovir的开发,以集中精力发现和推进其他在研疗法的开发,这些...
Source Link10月7日,ClinicalTrials.gov网站显示,辉瑞已终止两项Sisunatovir治疗呼吸道合胞病毒(RSV)感染的临床研究。据外媒Fierce Biotech报道,辉瑞的一位发言人表示:“Sisunatovir的临床开发面临持续的挑战,包括与抗酸药的药物相互作用。虽然辉瑞一直在努力解决这些挑战,但最终决定终止Sisunatovir的开发,以集中精力发现和推进其他在研疗法的开发,这些...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.